PODD

Insulet (United States)

$145.29

-4.72%
Nov 16, 2026
Bobby Quantitative Model
Insulet Corporation is a medical device company focused on diabetes care, best known for its Omnipod platform — a tubeless, wearable, disposable insulin infusion system controlled via smartphone that competes in the continuous subcutaneous insulin infusion (CSII) market alongside traditional tubed pumps and emerging automated insulin delivery systems. Insulet occupies a differentiated position as the leading tubeless patch-pump player, with a razor-and-blade model built on disposable pods and a growing installed base now exceeding 600,000 insulin-dependent users worldwide, giving it recurring revenue characteristics unusual for a hardware device maker. The current investor narrative is dominated by a sharp deterioration in sentiment following a high-risk FDA-flagged recall and voluntary correction of Omnipod 5 pods tied to insulin under-delivery, which drove the stock to a 52-week low in early 2026 and has left shares down more than 50% over the trailing year despite still-robust double-digit revenue growth. The debate now centers on whether the recall is a contained quality event or a structural reputational and competitive setback, with bulls pointing to 19% YoY revenue growth, expanding margins, and a deeply de-rated multiple, while bears highlight competitive pressure in automated insulin delivery and the persistent overhang of quality-control risk.

People also watch

Abbott Laboratories

Abbott Laboratories

ABT

Analysis
Medtronic plc

Medtronic plc

MDT

Analysis
Stryker Corporation

Stryker Corporation

SYK

Analysis
Boston Scientific

Boston Scientific

BSX

Analysis
Edwards Lifesciences

Edwards Lifesciences

EW

Analysis

BobbyInvestment Opinion: Should I buy PODD Today?

Rating: Hold with a constructive bias. The core thesis is that Insulet's operating fundamentals — 19.21% YoY revenue growth to $842.0M in Q3 2026, gross margin of 75.07%, and diluted EPS of $2.03 — have decoupled from a stock that has fallen 54.16% over the past year, but the unresolved FDA high-risk recall of Omnipod 5 pods keeps the risk/reward balanced rather than compelling. The analyst consensus of "buy" (15 Buy / 11 Hold / 0 Sell, mean 2.0) with an average target of $178.57 (+17.1% from $152.48) anchors the view that the selloff is overdone, yet six November 2026 Hold reiterations from Truist, Barclays, Citigroup, JP Morgan, Wells Fargo, and UBS show the Street is waiting for recall clarity before committing.

Supporting evidence is genuinely strong on four fronts: the forward PE of 19.28x against a trailing 80.98x implies the market is pricing a full earnings recovery to consensus EPS of $12.31, while PS has compressed from 30.88x in Q3 2025 to 7.38x today; revenue has risen sequentially every quarter of 2026 ($761.7M → $801.7M → $842.0M); gross margin expanded roughly 560bps from Q1 (69.46%) to Q3 (75.07%) with operating margin up from 16.03% to 22.54%; and TTM free cash flow of $260.0M plus a current ratio of 2.78 and debt-to-equity of 0.69 confirm the business is self-funding. The entire analyst range ($160.00 low to $200.00 high) sits above the current price — a rare configuration that signals the sell-side sees the market as oversold.

Three risks could invalidate the thesis: a second quality event or prolonged FDA remediation that breaks the $12.31 forward EPS estimate; competitive share loss in automated insulin delivery, which Zacks explicitly cites alongside the stock's underperformance; and valuation compression given EV/EBITDA of 39.89x and P/B of 13.20x versus a medical devices sector in the high-teens to low-20s on EBITDA. This Hold would upgrade to Buy on a confirmed FDA resolution or a decisive break above the $165–$170 resistance zone, and would downgrade to Sell on a break below the $126.40 52-week low or any guidance cut. On balance the stock looks fairly valued to modestly undervalued on forward earnings but expensive on current cash-flow multiples — a de-rated name whose cheapness is conditional on execution.

Sign up to view all

PODD 12-Month Price Forecast

The forward view is genuinely two-sided: operating momentum is strong and the valuation has de-rated to a multi-year trough, but the single variable that matters most — whether the Omnipod 5 recall is contained — remains unresolved. The base case (50% probability) assumes a gradual grind toward the $178.57 average target as the overhang fades, while the 30% bull case requires a clean FDA resolution to unlock the $200.00 high target and the 20% bear case prices a second quality event back to the $126.40 low. With 99% of revenue concentrated in the Omnipod platform and EV/EBITDA at 39.89x, the stock offers asymmetric upside only if execution holds, which is why the stance is neutral rather than bullish despite the +17.1% implied target upside. I would upgrade to bullish on a confirmed FDA resolution or a sustained break above $170, and downgrade to bearish on a break below $126.40 or any cut to the $12.31 forward EPS estimate.

Historical Price
Current Price $145.29
Average Target $170.00
High Target $200.00
Low Target $126.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Insulet (United States)'s 12-month outlook, with a consensus price target around $178.57 and implied upside of +22.9% versus the current price.

Average Target

$178.57

26 analysts

Implied Upside

+22.9%

vs. current price

Analyst Count

26

covering this stock

Price Range

$160 - $200

Analyst target range

Buy
15 (58%)
Hold
11 (42%)
Sell
0 (0%)

Coverage is broad and institutional, with 23 analysts covering PODD and a distribution of 15 Buy, 11 Hold, and 0 Sell — a consensus recommendation of "buy" with a recommendation mean of 2.0 that leans moderately bullish despite the stock's collapse. The average target price of $178.57 implies roughly +17.1% upside from the current $152.48, and notably even the lowest target of $160.00 sits about 4.9% above the current price, meaning the entire analyst range is above the market — a rare configuration that signals the sell-side views the current price as oversold. Consensus estimated revenue of $4.96 billion and EPS of $12.31 for the forward period underpin that optimism.

The target range of $160.00 to $200.00 is relatively tight (a spread of about 25% from low to high), which signals stronger conviction than a wide dispersion would, and the high target of $200.00 implies roughly +31% upside and would require multiple expansion back toward the mid-20s forward PE alongside continued 19% revenue growth and resolution of the recall overhang. The low target of $160.00 prices in a more conservative scenario — modest multiple recovery with margin stability but no re-rating — and even that assumes no further quality or competitive shocks. Institutional ratings show a pattern of steady, unenthusiastic coverage: the November 2026 updates from Truist, Barclays, Citigroup, JP Morgan, Wells Fargo, and UBS were all Hold/Neutral/Equal Weight reiterations, while Bernstein and RBC maintained Outperform and Jefferies maintained Buy, indicating the Street is bifurcated between those anchored on fundamentals and those waiting for recall clarity — a setup where the next catalyst (likely Q4 results or FDA resolution) will determine whether the consensus target holds.

Drowning in data?

Find the real signal!

Bulls vs Bears: PODD Investment Factors

The bear case currently rests on unresolved event risk — an FDA high-risk recall with no confirmed resolution — while the bull case rests on operating fundamentals that are visibly improving: 19.21% revenue growth, gross margin up roughly 560bps from Q1 to Q3, and EPS nearly doubling sequentially to $2.03. On balance the fundamental evidence is stronger than the sentiment evidence, since the de-rating to 7.38x PS and 19.28x forward PE has already priced a substantial amount of recall damage, and every one of 23 analyst targets sits above the current price. The single most important tension is whether the Omnipod 5 recall is a contained quality event or a structural reputational setback — a clean FDA resolution would likely trigger multiple expansion toward the $178–$200 target zone, while a second defect or a prolonged remediation would validate the falling-knife thesis and pressure the forward EPS estimate of $12.31 that the entire valuation now hinges on.

Bullish

  • Revenue re-accelerating at 19.2% YoY: Q3 2026 revenue of $842.0 million grew 19.21% versus $706.3 million in Q3 2025, and the sequential path ($761.7M → $801.7M → $842.0M) shows no demand destruction from the recall headlines. Consensus forward revenue of $4.96 billion implies continued double-digit expansion.
  • Margins expanding sharply despite recall: Gross margin climbed from 69.46% in Q1 2026 to 70.18% in Q2 and 75.07% in Q3, while operating margin rose from 16.03% to 22.54% over the same span. Diluted EPS accelerated from $1.30 to $1.37 to $2.03, evidence of manufacturing leverage and pricing power rather than a business under stress.
  • Entire analyst range above market price: The lowest of 23 analyst targets is $160.00, already 4.9% above the $152.48 price, with an average of $178.57 (+17.1%) and a high of $200.00 (+31%). A configuration where zero targets sit below the market is rare and signals the sell-side views the selloff as overdone.
  • Valuation collapsed to multi-year trough: PS fell from 30.88x in Q3 2025 to 7.38x in Q3 2026, and trailing PE of 80.98x compresses to a forward PE of just 19.28x on consensus EPS of $12.31. The market is pricing a full earnings recovery that, if delivered, leaves the stock cheap on forward numbers.

Bearish

  • FDA high-risk recall overhang unresolved: The FDA flagged a high-risk recall of Omnipod 5 pods over insulin under-delivery in April 2026, followed by a voluntary correction in March that drove the stock to its 52-week low. With no confirmed FDA resolution, the risk of further corrective actions, remediation costs, or litigation remains live and unquantified in the forward estimates.
  • Single-product concentration is total: International Omnipod contributed $836.6 million of the $842.0 million quarterly revenue, with the Drug Delivery line at just $5.5 million. Essentially 99% of the top line depends on one platform in one therapeutic category, so any pod-level quality or competitive shock hits the entire thesis.
  • EV/EBITDA of 39.9x is rich versus sector: While PS of 7.38x looks modest, EV/EBITDA of 39.89x and P/B of 13.20x sit well above a medical devices sector that typically trades in the high-teens to low-20s on EBITDA. The premium is entirely dependent on the forward earnings recovery materializing.
  • Street conviction is bifurcated and cautious: Despite 15 Buy ratings, the November 2026 updates from Truist, Barclays, Citigroup, JP Morgan, Wells Fargo, and UBS were all Hold/Neutral reiterations. A recommendation mean of 2.0 with 11 Holds shows a large cohort waiting for recall clarity rather than buying the dip.

PODD Technical Analysis

PODD is in a pronounced, sustained downtrend on a longer horizon, with the 1-year price change of -54.16% and a YTD decline of -46.10% reflecting a severe de-rating rather than a mere pullback. At the current price of $152.48, the stock sits at roughly 11.4% of its 52-week range (low $126.40 to high $354.88), meaning it is trading in the bottom decile of its annual band — a positioning that historically signals either deep value or a falling knife, and here the -62.33% max drawdown confirms the latter has been the dominant experience for holders. The distance to the 52-week high (roughly 57% below) underscores how much optimism has been wrung out of the name.

Short-term momentum, however, has turned sharply positive and diverges from the longer-term trend: the 1-month change of +13.85% and 3-month change of +6.38% contrast with the -54.16% 1-year performance, and the 6-month change of +3.40% suggests the stock has been basing since roughly mid-year. This divergence — a rising 1-month trend against a collapsing 1-year trend — is characteristic of a potential mean-reversion rally or bottoming process rather than a confirmed reversal, and the relative strength data reinforces it: relative strength versus SPY is +16.11 over 1 month and +9.21 over 3 months, even as it remains -66.43 over 1 year. The most recent session added +2.14% on the day, and the stock has recovered from an October trough near $130 to the current $152.48, a roughly 17% bounce off the lows that suggests buyers are stepping in around the $126–$130 support zone.

Key technical levels are well defined: support sits at the 52-week low of $126.40, with secondary support around the $130–$134 area that held repeatedly in September and October 2026, while resistance lies at the 52-week high of $354.88 — far out of reach — with more actionable near-term resistance in the $165–$170 zone where the stock failed in early August before the gap down to $133.26. A decisive breakout above $170 would signal that the post-recall downtrend is being reversed and could open a path toward the $200s, whereas a breakdown below $126.40 would confirm the falling-knife thesis and likely trigger momentum-driven selling. With a beta of 1.05, PODD's volatility is roughly in line with the market on a measured basis, but the -62.33% max drawdown and the violent single-day gap from $166.82 to $133.26 in early August demonstrate event-driven risk far exceeding what beta implies — position sizing should account for headline and recall-related gap risk rather than relying on beta alone.

Beta

1.05

1.05x market volatility

Max Drawdown

-62.3%

Largest decline past year

52-Week Range

$126-$355

Price range past year

Annual Return

-56.3%

Cumulative gain past year

PeriodPODD ReturnS&P 500
1m+3.0%-3.0%
3m-1.9%-3.6%
6m-7.2%-0.2%
1y-56.3%+10.1%
ytd-48.6%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

PODD Fundamental Analysis

Revenue is growing at a healthy clip and, importantly, appears to be re-accelerating: the most recent quarter (Q3 2026, ended September 30) delivered $842.0 million in revenue with 19.21% YoY growth versus $706.3 million in Q3 2025. The sequential trajectory is consistently upward — $761.7 million in Q1 2026, $801.7 million in Q2 2026, and $842.0 million in Q3 2026 — and the YoY growth rate of 19.21% compares favorably to the prior-year comparison base, indicating durable demand despite the recall headlines. International Omnipod contributed $836.6 million in the disclosed segment data, dwarfing the $5.5 million Drug Delivery line, confirming that the core pod franchise is essentially the entire growth engine; the investment case therefore hinges almost entirely on Omnipod volume and pricing power rather than diversification.

Profitability is robust and expanding, a notable contrast to the stock's collapse: Q3 2026 net income reached $141.1 million on a 16.76% net margin, with gross margin of 75.07% and operating margin of 22.54%, up meaningfully from Q1 2026's 69.46% gross margin and 16.03% operating margin. The gross margin progression — 69.46% in Q1, 70.18% in Q2, 75.07% in Q3 — reflects manufacturing leverage and a favorable mix, while diluted EPS climbed from $1.30 in Q1 to $1.37 in Q2 to $2.03 in Q3, a clear acceleration in bottom-line delivery. These margins are strong for a medical device manufacturer and suggest the company has genuine pricing power and scale economics, which makes the equity de-rating look increasingly disconnected from operating fundamentals.

Balance sheet and cash generation are solid but not fortress-like: the current ratio of 2.78 and debt-to-equity of 0.69 indicate comfortable liquidity and moderate leverage, while TTM free cash flow of $260.0 million and quarterly FCF of $66.4 million in Q3 (against $123.5 million of operating cash flow and $57.1 million of capex) show the business funds itself internally. ROE of 16.31% and ROA of 11.40% confirm efficient capital deployment, and cash on hand of $584.4 million provides a buffer; however, the Q1 2026 $300 million share repurchase and elevated capex ($57.1 million in Q3 alone) mean cash returns and investment are competing for the same dollars. The FCF yield implied by a $260 million TTM FCF against a roughly $20 billion market cap is only about 1.3%, which is thin and reflects a growth-oriented capital allocation rather than a cash-return story.

Quarterly Revenue

$842000000.0B

2026-09

Revenue YoY Growth

+19.2%

YoY Comparison

Gross Margin

75.1%

Latest Quarter

Free Cash Flow

$260000000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Drug Delivery
International Omnipod

Open an Account, get $2 TSLA now!

Valuation Analysis: Is PODD Overvalued?

Because net income is positive ($141.1 million in Q3 2026, TTM EPS positive), the PE ratio is the appropriate primary metric, and the trailing PE of 80.98x versus a forward PE of 19.28x is the single most important valuation signal in this dataset. That enormous gap — a roughly 76% compression from trailing to forward earnings — implies the market expects earnings to multiply over the next twelve months, consistent with consensus estimated EPS of $12.31 versus the trailing figure, and it means the stock is either cheap on forward earnings or the forward estimate is at risk if recall-related costs or competitive pressure bite. The PEG ratio of -1.97 is not meaningful given the sign distortion and should be disregarded.

On peer comparison, PODD's 7.38x PS and 3.46x EV/Sales look modest for a high-growth medical device name, but the EV/EBITDA of 39.89x and P/B of 13.20x are rich relative to a typical medical devices sector trading in the high-teens to low-20s on EV/EBITDA. The spread is stark: EV/EBITDA of ~40x versus a sector norm that would suggest a meaningful premium, while the forward PE of 19.28x versus a trailing 80.98x suggests the premium is entirely a function of expected earnings recovery rather than current profitability. The premium is defensible only if the 19% revenue growth and 75% gross margins persist and the recall proves contained; if either assumption falters, the multiple has substantial room to compress.

Historically, PODD's valuation has collapsed from its own elevated band: the PS ratio stood at 10.75x in Q3 2026 versus 25.52x in Q4 2025 and 30.88x in Q3 2025, and the PE ratio fell from 62.24x in Q3 2025 to 16.07x in Q3 2026 on the historical ratios data. This places the stock near the bottom of its multi-year valuation range — a classic setup where the market is pricing in either a value opportunity or fundamental deterioration, and the answer hinges on whether the recall is a one-time event. The P/B of 13.20x remains elevated versus its own history (5.73x in Q3 2026 per the historical series), suggesting book value has grown faster than the share price, which mechanically flatters the current multiple and warrants caution in reading it as outright cheapness.

PE

81.0x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 16x~294x

vs. Industry Avg

26.4x

Industry PE ~26.4x*

EV/EBITDA

39.9x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the fact that the forward valuation depends almost entirely on an earnings recovery that has not yet been proven. Trailing PE of 80.98x versus forward PE of 19.28x requires EPS to roughly quadruple toward the $12.31 consensus, and any recall-related remediation cost, inventory write-down, or pricing concession would hit that estimate directly. Revenue concentration is extreme — Omnipod delivered $836.6 million of $842.0 million in Q3 2026 — so a single product line carries essentially the whole company. Free cash flow of $260.0 million TTM against a roughly $20 billion market cap yields only about 1.3%, and Q3 capex of $57.1 million plus the $300 million Q1 2026 buyback leave limited cushion if cash generation slows.

Market and competitive risks are dominated by valuation compression and the automated insulin delivery arms race. EV/EBITDA of 39.89x and P/B of 13.20x sit well above a medical devices sector trading in the high-teens to low-20s on EBITDA, so the stock carries a premium that requires flawless execution to sustain. Beta of 1.05 suggests market-like volatility, but the -62.33% max drawdown and the August gap from $166.82 to $133.26 show that headline risk, not beta, is the real driver. The Zacks commentary explicitly cites competitive pressures alongside the stock's underperformance, and the bifurcated analyst stance — six Hold reiterations in November 2026 against Bernstein, RBC, and Jefferies Buys — means any negative competitive datapoint could tip the consensus target lower.

The worst-case scenario is a second quality event or a prolonged FDA remediation that forces the company to cut guidance, which would simultaneously break the $12.31 forward EPS estimate and compress the multiple back toward the sector. In that chain, the stock would retest the 52-week low of $126.40, roughly -17% from the current $152.48, and a break below that level would likely trigger momentum selling toward the $110–$120 area given the -62.33% historical max drawdown. Even the analyst low target of $160.00 assumes no further shocks, so the realistic downside in an adverse scenario is -17% to -25% from current levels, with tail risk extending further if the recall escalates into litigation or a market-share loss in automated insulin delivery.

FAQ

Ranked by severity: first, event risk from the FDA high-risk recall of Omnipod 5 pods over insulin under-delivery, which remains unresolved and could escalate into remediation costs, inventory write-downs, or litigation that break the $12.31 forward EPS estimate the valuation hinges on. Second, concentration risk — Omnipod delivered $836.6M of $842.0M in Q3 2026 revenue, so essentially the entire company depends on one platform in one therapeutic category. Third, valuation compression risk, with EV/EBITDA at 39.89x and P/B at 13.20x versus a sector in the high-teens to low-20s on EBITDA, leaving little cushion if growth slows. Fourth, competitive and sentiment risk in automated insulin delivery, which Zacks explicitly cites alongside the stock's underperformance, amplified by a short interest ratio of 3.45 days and a demonstrated single-day gap from $166.82 to $133.26 in early August.

The scenario framework is 50% base, 30% bull, 20% bear. The base case targets $160–$180 (centered on the $178.57 average target, +17.1%) and assumes revenue tracks the $4.96B consensus with gross margin in the 70–75% band and forward EPS of $12.31 broadly delivered. The bull case targets $185–$200 and requires a clean FDA resolution of the recall plus gross margin sustained above 75%, unlocking multiple expansion toward the mid-20s forward PE. The bear case targets $126–$145, retesting the $126.40 52-week low, on a second quality event, expanded recall scope, or competitive share loss in automated insulin delivery. The base case is most likely because it requires only that the overhang fades without a dramatic catalyst — the key assumption being that no second defect emerges and no material remediation charges hit the forward estimate.

The answer depends entirely on which multiple you trust. On forward earnings the stock looks modestly undervalued: forward PE of 19.28x against trailing PE of 80.98x implies the market is pricing a full recovery to consensus EPS of $12.31, and PS has compressed from 30.88x in Q3 2025 to 7.38x today, near the bottom of its multi-year range. On cash-flow multiples it still looks expensive: EV/EBITDA of 39.89x and P/B of 13.20x sit well above a medical devices sector that typically trades in the high-teens to low-20s on EBITDA. The market is therefore paying a fair-to-cheap price for future earnings while demanding a premium for current cash generation — a bet that the 19% growth and 75% gross margin persist and the recall proves contained. If either assumption falters, the forward multiple has meaningful room to compress.

The risk/reward is balanced-to-attractive but conditional. Upside to the $178.57 average target is +17.1% and to the $200.00 high target roughly +31%, and even the lowest of 23 targets ($160.00) sits 4.9% above the $152.48 price — a configuration that signals the sell-side sees the selloff as overdone. Against that, the downside case retests the $126.40 52-week low, about -17%, and a break there could extend toward $110–$120 given the -62.33% max drawdown. The deciding variable is the unresolved FDA high-risk recall of Omnipod 5 pods, which makes this a good buy for a patient investor who can tolerate a second quality event, and a poor entry for anyone needing near-term certainty. A staged approach — partial position now, add on a confirmed FDA resolution or a sustained break above $170 — best matches the evidence.

The profile favors a medium-to-long horizon of at least 12–24 months rather than short-term trading. The company is in a growth stage with 19.21% YoY revenue growth, a 75.07% gross margin, and no dividend (payout ratio of 0), so total return depends on earnings delivery and multiple recovery rather than income. Beta of 1.05 implies market-like measured volatility, but the -62.33% max drawdown and the August gap from $166.82 to $133.26 show event-driven risk far exceeding beta, which makes short-term positioning a bet on FDA headlines rather than fundamentals. Earnings visibility is decent but not high — the forward PE of 19.28x versus trailing 80.98x requires EPS to roughly quadruple, a recovery not yet proven. A staged accumulation over 12–24 months, sized to absorb a -17% to -25% adverse move, is the structure best supported by the data.